CCL20 is elevated during obesity and differentially regulated by NF-κB subunits in pancreatic β-cells

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1849, Issue 6, 2015, Pages 637-652

  Burke, Susan J ^a,b   Karlstad, Michael D ^c   Regal, Kellie M ^c   Sparer, Tim E ^b   Lu, Danhong ^d   Elks, Carrie M ^a   Grant, Ryan W ^a   Stephens, Jacqueline M ^a   Burk, David H ^a   Collier, J Jason ^a,b,c  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

^c UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY   (United States)

Author keywords

Chemokine; Cytokine; Diabetes; Inflammation; Innate immunity; Transcription

Indexed keywords

CHEMOKINE RECEPTOR CCR6; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLOOXYGENASE 2; E1A ASSOCIATED P300 PROTEIN; GAMMA INTERFERON; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR MAFA; TRANSCRIPTION FACTOR NKX6.1; TRANSCRIPTION FACTOR PDX 1; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; CCR6 PROTEIN, HUMAN; IL1B PROTEIN, MOUSE; RELA PROTEIN, MOUSE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HISTONE METHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID DIET; MALE; MOUSE; NEUTROPHIL; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; ANIMAL; BIOSYNTHESIS; DIABETES MELLITUS; GENETICS; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; RAT;

MUS; RATTUS;

ANIMALS; CHEMOKINE CCL20; DIABETES MELLITUS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; INTERLEUKIN-1BETA; MICE; MICE, OBESE; NF-KAPPA B; OBESITY; RATS; RECEPTORS, CCR6; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA;

EID: 84928136157     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2015.03.007     Document Type: Article

References (85)

1. Baker R.G., Hayden M.S., Ghosh S. NF-kappaB, inflammation, and metabolic disease. Cell Metab. 2011, 13:11-22.
2. Burke S.J., Collier J.J. Insulitis and diabetes: A perspective on islet inflammation. Immunome Res. 2014, 10. (in Press).
3. Donath M.Y., Schumann D.M., Faulenbach M., Ellingsgaard H., Perren A., Ehses J.A. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care 2008, 31(Suppl. 2):S161-S164.
4. Corbett J.A., Wang J.L., Sweetland M.A., Lancaster J.R., McDaniel M.L. Interleukin 1 beta induces the formation of nitric oxide by beta-cells purified from rodent islets of Langerhans. Evidence for the beta-cell as a source and site of action of nitric oxide. J. Clin. Invest. 1992, 90:2384-2391.
5. Collier J.J., Burke S.J., Eisenhauer M.E., Lu D., Sapp R.C., Frydman C.J., Campagna S.R. Pancreatic beta-cell death in response to Pro-inflammatory cytokines is distinct from genuine apoptosis. PLoS One 2011, 6:e22485.
6. Corbett J.A., Sweetland M.A., Wang J.L., Lancaster J.R., McDaniel M.L. Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:1731-1735.
7. Boni-Schnetzler M., Boller S., Debray S., Bouzakri K., Meier D.T., Prazak R., Kerr-Conte J., Pattou F., Ehses J.A., Schuit F.C., Donath M.Y. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 2009, 150:5218-5229.
8. Burke S.J., Updegraff B.L., Bellich R.M., Goff M.R., Lu D., Minkin S.C., Karlstad M.D., Collier J.J. Regulation of iNOS gene transcription by IL-1beta and IFN-gamma requires a coactivator exchange mechanism. Mol. Endocrinol. 2013, 27:1724-1742.
9. Burke S.J., Collier J.J. The gene encoding cyclooxygenase-2 is regulated by IL-1beta and prostaglandins in 832/13 rat insulinoma cells. Cell. Immunol. 2011, 271:379-384.
10. Heitmeier M.R., Scarim A.L., Corbett J.A. Interferon-gamma increases the sensitivity of islets of Langerhans for inducible nitric-oxide synthase expression induced by interleukin 1. J. Biol. Chem. 1997, 272:13697-13704.
11. Sarkar S.A., Lee C.E., Victorino F., Nguyen T.T., Walters J.A., Burrack A., Eberlein J., Hildemann S.K., Homann D. Expression and regulation of chemokines in murine and human type 1 diabetes. Diabetes 2012, 61:436-446.
12. Burke S.J., Lu D., Sparer T.E., Masi T., Goff M.R., Karlstad M.D., Collier J.J. NF-kappaB and STAT1 control CXCL1 and CXCL2 gene transcription. Am. J. Physiol. Endocrinol. Metab. 2014, 306:E131-E149.
13. Burke S.J., Goff M.R., Lu D., Proud D., Karlstad M.D., Collier J.J. Synergistic expression of the CXCL10 gene in response to IL-1beta and IFN-gamma involves NF-kappaB, phosphorylation of STAT1 at Tyr701, and acetylation of histones H3 and H4. J. Immunol. 2013, 191:323-336.
14. Burke S.J., Goff M.R., Updegraff B.L., Lu D., Brown P.L., Minkin S.C., Biggerstaff J.P., Zhao L., Karlstad M.D., Collier J.J. Regulation of the CCL2 gene in pancreatic beta-cells by IL-1beta and glucocorticoids: Role of MKP-1. PLoS One 2012, 7:e46986.
15. Tilstra J.S., Clauson C.L., Niedernhofer L.J., Robbins P.D. NF-kappaB in aging and disease. Aging Dis. 2011, 2:449-465.
16. Brown K.D., Claudio E., Siebenlist U. The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res. Ther. 2008, 10:212.
17. Ben-Neriah Y., Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat. Immunol. 2011, 12:715-723.
18. Ellrichmann G., Thone J., Lee D.H., Rupec R.A., Gold R., Linker R.A. Constitutive activity of NF-kappa B in myeloid cells drives pathogenicity of monocytes and macrophages during autoimmune neuroinflammation. J. Neuroinflammation 2012, 9:15.
19. Cai D. Neuroinflammation and neurodegeneration in overnutrition-induced diseases. Trends Endocrinol. Metab. 2013, 24:40-47.
20. Oeckinghaus A., Hayden M.S., Ghosh S. Crosstalk in NF-kappaB signaling pathways. Nat. Immunol. 2011, 12:695-708.
21. Beg A.A., Baldwin A.S. The I kappa B proteins: multifunctional regulators of Rel/NF-kappa B transcription factors. Genes Dev. 1993, 7:2064-2070.
22. Moser B., Wolf M., Walz A., Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 2004, 25:75-84.
23. Gerard C., Rollins B.J. Chemokines and disease. Nat. Immunol. 2001, 2:108-115.
24. Weisberg S.P., Hunter D., Huber R., Lemieux J., Slaymaker S., Vaddi K., Charo I., Leibel R.L., Ferrante A.W. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest. 2006, 116:115-124.
25. Kim C.S., Park H.S., Kawada T., Kim J.H., Lim D., Hubbard N.E., Kwon B.S., Erickson K.L., Yu R. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int. J. Obes. 2006, 30:1347-1355.
26. Martin A.P., Rankin S., Pitchford S., Charo I.F., Furtado G.C., Lira S.A. Increased expression of CCL2 in insulin-producing cells of transgenic mice promotes mobilization of myeloid cells from the bone marrow, marked insulitis, and diabetes. Diabetes 2008, 57:3025-3033.
27. Cowley M.J., Weinberg A., Zammit N.W., Walters S.N., Hawthorne W.J., Loudovaris T., Thomas H., Kay T., Gunton J.E., Alexander S.I., Kaplan W., Chapman J., O'Connell P.J., Grey S.T. Human islets express a marked proinflammatory molecular signature prior to transplantation. Cell Transplant. 2012, 21:2063-2078.
28. Merani S., Truong W.W., Hancock W., Anderson C.C., Shapiro A.M. Chemokines and their receptors in islet allograft rejection and as targets for tolerance induction. Cell Transplant. 2006, 15:295-309.
29. Citro A., Cantarelli E., Maffi P., Nano R., Melzi R., Mercalli A., Dugnani E., Sordi V., Magistretti P., Daffonchio L., Ruffini P.A., Allegretti M., Secchi A., Bonifacio E., Piemonti L. CXCR1/2 inhibition enhances pancreatic islet survival after transplantation. J. Clin. Invest. 2012, 122:3647-3651.
30. Hromas R., Gray P.W., Chantry D., Godiska R., Krathwohl M., Fife K., Bell G.I., Takeda J., Aronica S., Gordon M., Cooper S., Broxmeyer H.E., Klemsz M.J. Cloning and characterization of exodus, a novel beta-chemokine. Blood 1997, 89:3315-3322.
31. Matsui T., Akahoshi T., Namai R., Hashimoto A., Kurihara Y., Rana M., Nishimura A., Endo H., Kitasato H., Kawai S., Takagishi K., Kondo H. Selective recruitment of CCR6-expressing cells by increased production of MIP-3 alpha in rheumatoid arthritis. Clin. Exp. Immunol. 2001, 125:155-161.
32. Jafarzadeh A., Bagherzadeh S., Ebrahimi H.A., Hajghani H., Bazrafshani M.R., Khosravimashizi A., Nemati M., Gadari F., Sabahi A., Iranmanesh F., Mohammadi M.M., Daneshvar H. Higher circulating levels of chemokine CCL20 in patients with multiple sclerosis: Evaluation of the influences of chemokine gene polymorphism, gender, treatment and disease pattern. J. Mol. Neurosci. 2014, 53:500-505.
33. Ylipaasto P., Smura T., Gopalacharyulu P., Paananen A., Seppanen-Laakso T., Kaijalainen S., Ahlfors H., Korsgren O., Lakey J.R., Lahesmaa R., Piemonti L., Oresic M., Galama J., Roivainen M. Enterovirus-induced gene expression profile is critical for human pancreatic islet destruction. Diabetologia 2012, 55:3273-3283.
34. Sato K., Kawasaki H., Nagayama H., Enomoto M., Morimoto C., Tadokoro K., Juji T., Takahashi T. Chemokine receptor expressions and responsiveness of cord blood T cells. J. Immunol. 2001, 166:1659-1666.
35. Christopherson K., Brahmi Z., Hromas R. Regulation of naive fetal T-cell migration by the chemokines Exodus-2 and Exodus-3. Immunol. Lett. 1999, 69:269-273.
36. Kucharzik T., Hudson J.T., Waikel R.L., Martin W.D., Williams I.R. CCR6 expression distinguishes mouse myeloid and lymphoid dendritic cell subsets: demonstration using a CCR6 EGFP knock-in mouse. Eur. J. Immunol. 2002, 32:104-112.
37. Brandes M., Legler D.F., Spoerri B., Schaerli P., Moser B. Activation-dependent modulation of B lymphocyte migration to chemokines. Int. Immunol. 2000, 12:1285-1292.
38. Krzysiek R., Lefevre E.A., Bernard J., Foussat A., Galanaud P., Louache F., Richard Y. Regulation of CCR6 chemokine receptor expression and responsiveness to macrophage inflammatory protein-3alpha/CCL20 in human B cells. Blood 2000, 96:2338-2345.
39. Robertson M.J., Williams B.T., Christopherson K., Brahmi Z., Hromas R. Regulation of human natural killer cell migration and proliferation by the exodus subfamily of CC chemokines. Cell. Immunol. 2000, 199:8-14.
40. Schutyser E., Struyf S., Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 2003, 14:409-426.
41. Diana J., Simoni Y., Furio L., Beaudoin L., Agerberth B., Barrat F., Lehuen A. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat. Med. 2013, 19:65-73.
42. Battaglia M. Neutrophils and type 1 autoimmune diabetes. Curr. Opin. Hematol. 2014, 21:8-15.
43. Valle A., Giamporcaro G.M., Scavini M., Stabilini A., Grogan P., Bianconi E., Sebastiani G., Masini M., Maugeri N., Porretti L., Bonfanti R., Meschi F., De Pellegrin M., Lesma A., Rossini S., Piemonti L., Marchetti P., Dotta F., Bosi E., Battaglia M. Reduction of circulating neutrophils precedes and accompanies type 1 diabetes. Diabetes 2013, 62:2072-2077.
44. Hohmeier H.E., Mulder H., Chen G., Henkel-Rieger R., Prentki M., Newgard C.B. Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion. Diabetes 2000, 49:424-430.
45. Janjic D., Maechler P., Sekine N., Bartley C., Annen A.S., Wolheim C.B. Free radical modulation of insulin release in INS-1 cells exposed to alloxan. Biochem. Pharmacol. 1999, 57:639-648.
46. Collier J.J., Fueger P.T., Hohmeier H.E., Newgard C.B. Pro- and antiapoptotic proteins regulate apoptosis but do not protect against cytokine-mediated cytotoxicity in rat islets and beta-cell lines. Diabetes 2006, 55:1398-1406.
47. Markert M., Andrews P.C., Babior B.M. Measurement of O2- production by human neutrophils. The preparation and assay of NADPH oxidase-containing particles from human neutrophils. Methods Enzymol. 1984, 105:358-365.
48. Donath M.Y., Boni-Schnetzler M., Ellingsgaard H., Halban P.A., Ehses J.A. Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends Endocrinol. Metab. 2010, 21:261-267.
49. McGillicuddy F.C., Harford K.A., Reynolds C.M., Oliver E., Claessens M., Mills K.H., Roche H.M. Lack of interleukin-1 receptor I (IL-1RI) protects mice from high-fat diet-induced adipose tissue inflammation coincident with improved glucose homeostasis. Diabetes 2011, 60:1688-1698.
50. Hayden M.S., Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008, 132:344-362.
51. Jobin C., Panja A., Hellerbrand C., Iimuro Y., Didonato J., Brenner D.A., Sartor R.B. Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor kappaB super-repressor in human intestinal epithelial cells. J. Immunol. 1998, 160:410-418.
52. Ueda A., Okuda K., Ohno S., Shirai A., Igarashi T., Matsunaga K., Fukushima J., Kawamoto S., Ishigatsubo Y., Okubo T. NF-kappa B and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J. Immunol. 1994, 153:2052-2063.
53. Newton R., Kuitert L.M., Bergmann M., Adcock I.M., Barnes P.J. Evidence for involvement of NF-kappaB in the transcriptional control of COX-2 gene expression by IL-1beta. Biochem. Biophys. Res. Commun. 1997, 237:28-32.
54. Moorthy A.K., Savinova O.V., Ho J.Q., Wang V.Y., Vu D., Ghosh G. The 20S proteasome processes NF-kappaB1 p105 into p50 in a translation-independent manner. EMBO J. 2006, 25:1945-1956.
55. Medzhitov R., Horng T. Transcriptional control of the inflammatory response. Nat. Rev. Immunol. 2009, 9:692-703.
56. Covic M., Hassa P.O., Saccani S., Buerki C., Meier N.I., Lombardi C., Imhof R., Bedford M.T., Natoli G., Hottiger M.O. Arginine methyltransferase CARM1 is a promoter-specific regulator of NF-kappaB-dependent gene expression. EMBO J. 2005, 24:85-96.
57. Vo N., Goodman R.H. CREB-binding protein and p300 in transcriptional regulation. J. Biol. Chem. 2001, 276:13505-13508.
58. Olza J., Aguilera C.M., Gil-Campos M., Leis R., Bueno G., Martinez-Jimenez M.D., Valle M., Canete R., Tojo R., Moreno L.A., Gil A. Myeloperoxidase is an early biomarker of inflammation and cardiovascular risk in prepubertal obese children. Diabetes Care 2012, 35:2373-2376.
59. Guo S., Dai C., Guo M., Taylor B., Harmon J.S., Sander M., Robertson R.P., Powers A.C., Stein R. Inactivation of specific beta cell transcription factors in type 2 diabetes. J. Clin. Invest. 2013, 123:3305-3316.
60. Li C.R., Mueller E.E., Bradley L.M. Islet antigen-specific Th17 cells can induce TNF-alpha-dependent autoimmune diabetes. J. Immunol. 2014, 192:1425-1432.
61. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
62. Dinarello C.A., Donath M.Y., Mandrup-Poulsen T. Role of IL-1beta in type 2 diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 2010, 17:314-321.
63. Rabinovitch A., Suarez-Pinzon W.L., Sorensen O., Bleackley R.C., Power R.F. IFN-gamma gene expression in pancreatic islet-infiltrating mononuclear cells correlates with autoimmune diabetes in nonobese diabetic mice. J. Immunol. 1995, 154:4874-4882.
64. Boni-Schnetzler M., Thorne J., Parnaud G., Marselli L., Ehses J.A., Kerr-Conte J., Pattou F., Halban P.A., Weir G.C., Donath M.Y. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J. Clin. Endocrinol. Metab. 2008, 93:4065-4074.
65. Maedler K., Sergeev P., Ris F., Oberholzer J., Joller-Jemelka H.I., Spinas G.A., Kaiser N., Halban P.A., Donath M.Y. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 2002, 110:851-860.
66. Grant R.W., Dixit V.D. Adipose tissue as an immunological organ. Obesity (Silver Spring) 2015, 23:512-518.
67. Grant R.W., Dixit V.D. Mechanisms of disease: inflammasome activation and the development of type 2 diabetes. Front. Immunol. 2013, 4:50.
68. Cnop M., Abdulkarim B., Bottu G., Cunha D.A., Igoillo-Esteve M., Masini M., Turatsinze J.V., Griebel T., Villate O., Santin I., Bugliani M., Ladriere L., Marselli L., McCarthy M.I., Marchetti P., Sammeth M., Eizirik D.L. RNA sequencing identifies dysregulation of the human pancreatic islet transcriptome by the saturated fatty acid palmitate. Diabetes 2014, 63:1978-1993.
69. Nepom G.T., Ehlers M., Mandrup-Poulsen T. Anti-cytokine therapies in T1D: Concepts and strategies. Clin. Immunol. 2013, 149:279-285.
70. Atkinson M.A., Eisenbarth G.S., Michels A.W. Type 1 diabetes. Lancet 2014, 383:69-82.
71. Donath M.Y., Shoelson S.E. Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 2011, 11:98-107.
72. Yeung W.C., Al-Shabeeb A., Pang C.N., Wilkins M.R., Catteau J., Howard N.J., Rawlinson W.D., Craig M.E. Children with islet autoimmunity and enterovirus infection demonstrate a distinct cytokine profile. Diabetes 2012, 61:1500-1508.
73. Perez F., Oyarzun A., Carrasco E., Angel B., Albala C., Santos J.L. Plasma levels of interleukin-1beta, interleukin-2 and interleukin-4 in recently diagnosed type 1 diabetic children and their association with beta-pancreatic autoantibodies. Rev. Med. Chil. 2004, 132:413-420.
74. van Poppel P.C., van Asseldonk E.J., Holst J.J., Vilsboll T., Netea M.G., Tack C.J. The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance. Diabetes Obes. Metab. 2014, 16:1269-1273.
75. van Asseldonk E.J., Stienstra R., Koenen T.B., Joosten L.A., Netea M.G., Tack C.J. Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 2011, 96:2119-2126.
76. Larsen C.M., Faulenbach M., Vaag A., Volund A., Ehses J.A., Seifert B., Mandrup-Poulsen T., Donath M.Y. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 2007, 356:1517-1526.
77. Coppieters K.T., Dotta F., Amirian N., Campbell P.D., Kay T.W., Atkinson M.A., Roep B.O., von Herrath M.G. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J. Exp. Med. 2012, 209:51-60.
78. Sarikonda G., Pettus J., Phatak S., Sachithanantham S., Miller J.F., Wesley J.D., Cadag E., Chae J., Ganesan L., Mallios R., Edelman S., Peters B., von Herrath M. CD8 T-cell reactivity to islet antigens is unique to type 1 while CD4 T-cell reactivity exists in both type 1 and type 2 diabetes. J. Autoimmun. 2014, 50:77-82.
79. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 2004, 89:2548-2556.
80. Duffaut C., Zakaroff-Girard A., Bourlier V., Decaunes P., Maumus M., Chiotasso P., Sengenes C., Lafontan M., Galitzky J., Bouloumie A. Interplay between human adipocytes and T lymphocytes in obesity: CCL20 as an adipochemokine and T lymphocytes as lipogenic modulators. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1608-1614.
81. Mackay C.R. Moving targets: cell migration inhibitors as new anti-inflammatory therapies. Nat. Immunol. 2008, 9:988-998.
82. Liston A., Kohler R.E., Townley S., Haylock-Jacobs S., Comerford I., Caon A.C., Webster J., Harrison J.M., Swann J., Clark-Lewis I., Korner H., McColl S.R. Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response. J. Immunol. 2009, 182:3121-3130.
83. Honkanen J., Nieminen J.K., Gao R., Luopajarvi K., Salo H.M., Ilonen J., Knip M., Otonkoski T., Vaarala O. IL-17 immunity in human type 1 diabetes. J. Immunol. 2010, 185:1959-1967.
84. Schulthess F.T., Paroni F., Sauter N.S., Shu L., Ribaux P., Haataja L., Strieter R.M., Oberholzer J., King C.C., Maedler K. CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling. Cell Metab. 2009, 9:125-139.
85. Oshima H., Taketo M.M., Oshima M. Destruction of pancreatic beta-cells by transgenic induction of prostaglandin E2 in the islets. J. Biol. Chem. 2006, 281:29330-29336.